

# Kadcyla (ado-trastuzumab emtansine, T-DM1) — HCPCS J9354

CARECOST ESTIMATE · BILLING  
CHEAT SHEET

Genentech (Roche) 100 mg + 160 mg single-dose vials IV q3w (90 min cycle 1, 30 min cycles 2+) Reviewed: May 22, 2026 ASP: Q2 2026

<b>HCPCS</b> <b>J9354</b> 1 mg = 1 unit	<b>DOSE</b> <b>3.6 mg/kg</b> q3w (both mBC + KATHERINE)	<b>MODIFIER</b> <b>JZ+JW</b> JW for vial waste (common)	<b>ADMIN CPT</b> <b>96413+96415</b> Cycle 1; 96413 only cycles 2+	<b>MEDICARE ASP+6%</b> <b>\$42.198</b> /mg · ~\$10,971/260 mg dose
---	---	---	---	--

CODES & NDC	
HCPCS	J9354 — "Inj, ado-trastuzumab emt 1mg" (permanent)
NDC 100 MG	50242-088-01 (10) / 50242-0088-01 (11) — N4
NDC 160 MG	50242-087-01 (10) / 50242-0087-01 (11) — N4
VIALS	100 mg + 160 mg single-dose lyophilized; reconstitute 100 mg/5 mL or 160 mg/8 mL SWFI → 20 mg/mL. Dilute in <b>0.9% NaCl 250 mL only (NOT D5W)</b> .
BENEFIT	Medical (provider buy-and-bill); not specialty pharmacy

- ### DOSING & VIAL MATH
- **3.6 mg/kg IV q3w** for both indications
  - mBC: until progression / intolerable toxicity
  - KATHERINE adjuvant: **14 cycles total**
  - 70 kg → 252 mg → 1×100 + 1×160 = 260 mg (8 mg waste)
  - 85 kg → 306 mg → 2×160 = 320 mg (14 mg waste)
  - Cycle 1 = 90 min infusion + 90 min observation
  - Cycles 2+ = 30 min infusion + 30 min observation
  - 0.20- or 0.22-micron PES in-line filter required

KADCYLA (J9354) VS ENHERTU (J9358)		
	KADCYLA (T-DM1)	ENHERTU (T-DXD)
HCPCS	J9354	J9358
Payload	DM1 maytansinoid	Deruxtecan (Topo-I)
Dose	3.6 mg/kg q3w	5.4 (6.4 GE) mg/kg q3w
HER2 tier	HER2+ only	+ HER2-low/ultralow/mutant

**NOT interchangeable.** Wrong J-code = automated denial. Confirm brand + J-code + dose at order, pharm verify, and claim coding.

ICD-10 — HER2+ BREAST	
CODE	FOR
C50.011-C50.929	Malignant neoplasm of breast (subsite + laterality + sex digits)
C77.x / C78.x / C79.x	Metastatic sites (mBC indication — code all known mets)
Z51.11	Encounter for antineoplastic chemo (primary encounter code)
Z51.12	Encounter for immunotherapy (some payers prefer for ADCs)
Z85.3	Personal Hx of breast Ca (selective use, KATHERINE)

**HER2+ status lives in pathology, not ICD-10.** Always attach HER2 IHC/ISH report (IHC 3+ or 2+/ISH+). For KATHERINE, attach post-neoadjuvant surgical path with ypT/ypN residual invasive disease.

- ### TOP DENIALS — FIX LIST
- **#1: HER2 doc missing** → attach IHC/ISH path report (IHC 3+ or 2+/ISH+)
  - **HER2-low / ultralow ordered Kadcyla** → switch to Enhertu (J9358)
  - **Wrong J-code (J9354 vs J9358)** → reconfirm brand + dose + J-code
  - **mBC step missing** → document prior trastuzumab + taxane (and Enhertu failure if req)
  - **KATHERINE missing residual-disease path** → attach surgical path with ypT/ypN call
  - **LFT / LVEF baseline missing** → chart baseline AST/ALT/T-bili + echo/MUGA
  - **Wrong admin code (96365)** → resubmit 96413 (+96415 cycle 1)
  - **JW waste missing** → add separate JW line with discarded mg
  - **Dose > 3.6 mg/kg** → recalc; FDA-label-capped at 3.6

## ADMINISTRATION & MODIFIERS

CODE	WHEN
96413	Chemo IV first hour — every cycle
96415	Each addl hour — cycle 1 only (90 min)
96365	<b>NOT appropriate</b> — ADC bills as chemo admin per CPT
JZ	Administered-units line (req since 7/1/23)
JW	Waste-units line (separate)

**Worked example (70 kg, 3.6 mg/kg):** Line 1: J9354 × 252 units + JZ. Line 2: J9354 × 8 units + JW. Line 3: 96413 + 96415 (cycle 1) or 96413 only (cycles 2+).

## PAYERS (MAY 2026)

PAYER	PA	NOTES
UnitedHealthcare	Yes	HER2 strict; Optum site-of-care steers HOPD out cycles 2+
Aetna	Yes	CPB 0244; KATHERINE needs residual-disease path
BCBS plans	Yes	NCCN-aligned; plan-specific site-of-care
Medicare (Original)	No PA	MAC LCDs; on-label coverage with HER2 doc
MA / Medicaid	Varies	Often commercial-style UM

## MEDICARE REIMBURSEMENT (Q2 2026)

FIELD	VALUE
ASP + 6%	<b>\$42.198 / mg</b> (eff. 4/1 – 6/30/2026)
252 mg (70 kg admin)	~\$10,633.90
260 mg billed (w/ 8 mg waste)	<b>~\$10,971.48 / cycle</b>
Annual mBC (~17 cycles)	~\$186,515
KATHERINE total (14 cycles)	~\$153,601

## PATIENT ASSISTANCE — GENENTECH ACCESS SOLUTIONS

- **Phone:** 1-866-422-2377 (Genentech Access Solutions)
- **Web:** genentech-access.com / kadcyla.com
- **Commercial copay:** up to **\$25,000/year** (excludes federal)
- **Genentech Patient Foundation:** free product for uninsured / underinsured (~≤ 500% FPL)
- **Medicare:** PAN Foundation, HealthWell, CancerCare (verify open breast funds quarterly)

**THREE BOXED WARNINGS:** (1) Hepatotoxicity — LFTs before each dose (rare fatal hepatic failure). (2) LV dysfunction — LVEF baseline + q3mo. (3) Embryo-fetal toxicity — pregnancy test + contraception ≥ 7 mo post-dose.